Written by Modality Solutions
Posted on: December 9, 2019
A Wall Street Journal, October 30, 2019 article announced one of the most important breakthroughs since the use of penicillin, a cure for Ebola. Although Modality Solutions is not mentioned in this article, it is important to note our involvement in the clinical trial phase that ultimately led to the successful development of a cure for Ebola. Modality Solutions was asked to assist with this clinical study because of our reputation and expertise in the field, as well as previous collaborations with BARDA, CDC, and NIH during the 2015 – 2016 Ebola outbreak in West Africa. The Mitchell Group (TMG) and Leidos Biomed, working with the US National Institute of Health (NIH) and World Health Organization (WHO) requested our assistance for optimizing storage and transport of time and temperature-sensitive products, such as the investigational drugs, biological specimens, and laboratory reagents involved in the clinical trial. In February and March 2019, our Subject Matter Experts (SMEs) traveled to the eastern provinces of the Democratic Republic of Congo (DRC) to evaluate and address cold chain management deficiencies. During their time in country, they conducted four site assessments, qualified critical equipment for the study, and conducted training for cold chain compliance for the local staff.